Skip to main content
Download PDF

Aberrant activation of TGF-β/ROCK1 enhances stemness during prostatic stromal hyperplasia

Cell Communication and Signaling volume 22, Article number: 257 (2024) Cite this article

Abstract

Benign prostatic hyperplasia (BPH) is a multifactorial disease in which abnormal growth factor activation and embryonic reawakening are considered important factors. Here we demonstrated that the aberrant activation of transforming growth factor β (TGF-β)/Rho kinase 1 (ROCK1) increased the stemness of BPH tissue by recruiting mesenchymal stem cells (MSCs), indicating the important role of embryonic reawakening in BPH. When TGF-β/ROCK1 is abnormally activated, MSCs are recruited and differentiate into fibroblasts/myofibroblasts, leading to prostate stromal hyperplasia. Further research showed that inhibition of ROCK1 activation suppressed MSC migration and their potential for stromal differentiation. Collectively, our findings suggest that abnormal activation of TGF-β/ROCK1 regulates stem cell lineage specificity, and the small molecule inhibitor GSK269962A could target ROCK1 and may be a potential treatment for BPH.

Graphical Abstract

Introduction

Benign prostatic hyperplasia (BPH) is a common urological disease that affects older men worldwide [1, 2]. Due to the increase in the aging population worldwide, the incidence and prevalence of BPH have rapidly increased [3]. Approximately 50% of men over 60 years of age and 80% of men over 80 years of age are affected by BPH [4, 5]. Lower urinary tract symptoms (LUTS) related to BPH, recurrent urinary tract infections and acute urinary retention substantially impact men’s health and quality of life [6]. BPH is defined as the uncontrolled proliferation of connective tissue, smooth muscle, and glandular epithelium within the transitional zone of the prostate [7, 8], but the etiology of BPH is not fully understood and various pathways involving hormones, growth factors, inflammation, embryonic reawakening, and stem cells have been hypothesized to contribute to its pathogenesis [9].

During early development, the prostate undergoes a period of rapid growth and differentiation. BPH is believed to be a recapitulation of this early developmental process [9,10,11]. Histological analysis of BPH nodules revealed that they consist of stromal or mixed cell types [12]. In embryonic prostate development, prostatic rudiments emerge as buds from the urethral epithelium. These buds then expand into condensed clusters of mesenchymal fibroblasts in response to androgens [13]. BPH nodules undergo a comparable developmental process. Embryonic growth signals, such as TGF-β, recruit mesenchymal stem cells (MSCs) from the bone marrow, leading to the induction of new proliferative nodules within the mesenchyme [14].

Aberrant transforming growth factor β (TGF-β) signaling is involved in the pathogenesis of BPH, resulting in stromal proliferation, epithelial-mesenchymal transition (EMT), transdifferentiation, and extracellular matrix production [15,16,17,18]. Moreover, the expression of TGF-β receptor II protein in patients with BPH was shown to have a significant correlation with prostate volume and BPH inflammation [19]. TGF-β signal transduction involves both Smad-dependent and non-Smad-dependent pathways. Prostatic stromal cells positive for phosphorylated Smad2/3 (p-Smad2/3) show age-related expansion and accumulation, consistent with profibrotic TGF-β activation. Additionally, p-Smad2/3 both upregulates and downregulates mesenchymal and epithelial markers in prostate epithelial cells, facilitating EMT and contributing to the progression of BPH [20]. The Smad-independent pathways involved include the Rho kinase 1 (ROCK1) pathway, the phosphatidylinositol 3-kinase/protein kinase B pathway, the non-Smad JNK/p38 pathway, and the mitogen-activated protein kinase pathway [21, 22]. ROCK1 plays a regulatory role in various biological processes, such as actin cytoskeletal organization, cell adhesion, migration, proliferation, survival, and permeability [23, 24]. Notably, the TGF-β-activated ROCK1 signaling pathway is a determinant for the lineage commitment of MSCs in the abnormal deposition of collagen [25,26,27].

The existence of MSCs in BPH has been documented, highlighting their involvement in the disease [28, 29]. Our previous study identified a subset of MSCs activated by TGF-β in prostatic stromal hyperplasia [30]. The leptin receptor serves as a marker for prospective identification and in vivo fate mapping of bone marrow MSCs. LepR+ MSCs exhibit stemness properties, including self-renewal and the potential to differentiate into multiple cell types [31]. Stemness encompasses the intrinsic capacity of a cell to maintain its lineage, generate differentiated cells, and interact with its microenvironment to regulate quiescence, proliferation, and regeneration, thereby allowing the cell to give rise to all cell types in the adult organism [32]. However, the investigation of stemness within prostate tissue in BPH remains largely unexplored and warrants further scientific inquiry. Recently, TGF-β was shown to regulate the expression of stemness factors, suggesting that TGF-β may enhance stemness by recruiting MSCs, leading to the reawakening of the prostate stroma [33, 34].

In summary, this study investigated the relationship between TGF-β signaling, stromal hyperplasia, and stemness in BPH. Additionally, we explored the role of LepR+ MSCs and the ROCK1 signaling pathway in the pathogenesis of BPH, while also validating the potential of ROCK1 as a therapeutic target. Importantly, this study provides strong support for the theory of embryonic reawakening in BPH.

Methods and materials

Human specimens

A total of 35 BPH specimens were collected from patients with BPH who underwent transurethral prostate resection in the Department of Urology, the Third Xiangya Hospital of Central South University. As controls, 9 normal prostates were obtained from bladder tumor patients younger than 50 years who underwent radical cystoprostatectomy. The normal prostates were reviewed by three pathologists to confirm that they were normal prostate tissue without any evidence of cancer invasion. The stromal/epithelial ratio was approximately 2:1. This experiment complies with the Declaration of Helsinki and was performed under the oversight and regulations of the ethics committee of the Third Xiangya Hospital (No. 22239).

Animal experiments

Transgenic animal experiments were carried out on 4- to 10-week-old mice. Trangenic Leprtm2(cre)Rck/J (Stock No. 008320) and Gt(ROSA26)Sor(tdTomato-WPRE) (Stock No. 007909) mice were purchased from Jackson Laboratories (California, USA). LepR-Cre mice were crossed with tdTomato transgenic mice to generate LepR-tdTomato mice. Mouse genotyping was performed under the guidance of the JAX genotyping protocols, and primer sequences are listed in Table S1. All mice were maintained under specific pathogen-free conditions with 12 h light/12 h dark. The treatment lasted for 4-weeks and involved administering the ROCK inhibitor GSK269962A (5 mg/kg, MCE) or the equivalent dose of solvent was injected intraperitoneally four times a week to male wild-type mice aged 8-weeks. Phenylephrine (PE) injection was used to initiate the treatment. The animal experiment was authorized by the ethics committee of Central South University (Reference No. 2021sydw0039).

Parabiosis model

Parabiosis mouse models were constructed as previously described [35]. Nine six-week-old male LepR-tdTomato (LepR-cre;tdTomatofl/−) mice were randomly surgically conjoined to a wild-type male littermate (Strain matched). The successful establishment of shared blood circulation was proven by flow cytometry of peripheral blood. The littermates were injected subcutaneously with PE (10 mg/kg−1/day−1), while 3'-O-CH3 modified siROCK1 (Sangong, China) or the same mock as the control was injected into the tail vein for 4 weeks prior to sacrifice. Mice were anesthetized with tribromoethanol, and blood and prostate tissue were collected from the wild-type littermates for analysis.

Hematoxylin and Eosin (HE) and Masson’s trichrome staining

For HE staining, paraffin-embedded tissues were dewaxed, rehydrated, HE stained, and dehydrated. Masson’s trichrome staining was performed according to standard procedures using the Trichrome Stain (Masson) kit (Sigma-Aldrich).

Immunohistochemistry and immunofluorescence

Five-micrometer slices were cut from formalin-fixed, OCT or paraffin-embedded specimens. The standard immunochemistry procedure of was followed, and then, the sections were incubated with the corresponding primary antibody at 4℃ overnight, followed by a 1-h incubation with biotinylated secondary antibodies or fluorescent secondary antibodies at room temperature. Representative images from each stained slice were captured by Imager.M2 (Zeiss, Germany). Microscopic images were assessed using Image J (https://imagej.nih.gov/ij/) to calculate the integral optical density (IOD) and the area of each picture. The average optical density was defined as the integrated optical density divided by area.

Wound healing and Transwell assays

A scratch wound healing assay was performed to examine the collective migration of LepR+ MSCs. After transfection of LepR+ cells with 100 nM siROCK1 (RiboBio, China) as described in the manual, the cells were added to a 6-well plate containing 2 ml of serum-free α-MEM with or without TGF-β (10 ng/ml, Sino Biological, China). After culture for 12 h, a scratch was made with a pipette tip. The width of the scratch gaps was recorded. The cells were cultured for 24 h. Then the width of the wound gaps was photographed. For Transwell migration assays, the siROCK1-transfected cells were counted and reseeded on the upper face of Transwell migration chambers (Costar 3422, Corning). Then, 500 μl of α-MEM with 10% FBS was added to the lower chamber. After culture for 24 h, the Transwell was removed and fixed with 0.4% paraformaldehyde. Then, 0.1% crystal violet was added for 15 min, and the cells were washed twice with PBS. The cells on the upper surface were wiped away. Cells attached to the lower surface were observed under a microscope (Nikon, Japan) and photographed.

Flow cytometry

Mouse peripheral blood was collected using anticoagulation tubes, lysed by red blood lysis solution (Solarbio, # R1010) and resuspended by adding 0.5% BSA PBS buffer. Nonspecific antibody binding to the FC receptor was blocked by preincubating the cells with Trustain Fcx PLUS (Biolegend, #156,604, reactive to CD16/CD32), and samples were then stained with corresponding antibodies and analyzed by flow cytometry.

RT‒qPCR

Total RNA was prepared by using TRIzol and reverse‐transcribed into cDNA with the NovoScript Plus All-In-One kit (Novoprotein, China). Real‐time quantitative PCR (RT–qPCR) was performed using the 2 × (Selleck, USA) and FTC 3000 Real‐time PCR system (Funglyn Biotech, CA), with GAPDH as a reference control. Primer information is detailed in Table S1.

Western blot

Total protein was extracted from cell samples, and the concentration was determined using a BCA protein assay kit (Elabscience, China). Samples were separated by sodium dodecyl sulfate/polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes. Blots were incubated with primary antibodies followed by HRP‐conjugated secondary antibodies and developed with enhanced chemiluminescence (Advansta, USA). Antibody information is detailed in Table S2.

Isolation and culture of mouse tdTomato-labeled LepR + cells

8-week-old LepR-tdTomato mice were euthanized and the prostate ventral lobe was carefully harvested and dissected under a microscope, and then minced and digested with prewarmed collagenase (Gibico, #17,101,015) solution (Collagenase type II was diluted to a final concentration of 1 mg/mL in α-MEM.) for 3 h at 37 °C. The dissociated tissue chunks were further washed with PBS once and placed in 0.25% trypsin for 10 min at 37 °C, and digestion was terminated by adding 5% FBS (Biological Industries, Israel), followed by centrifugation at 300 g for 5 min. Subsequently, the dissociated cell suspension was filtered with a 70-mm nylon cell strainer. The dissociated prostate cells were stained for 15 min on ice with CD45. Cell sorting was performed on a FACS Aria II system (BD). The tdTomato+ CD45– cells were sorted and cultured with α-MEM containing 1% penicillin/streptomycin (PS) sulfate (Thermo Scientific, USA), and 10% FBS at 37 °C in a 5% CO2 humidified incubator.

Multilineage differentiation

Prostatic LepR+ cells were isolated as abovementioned. The cells were seeded onto a 48-well plate and cultured in growth medium (α-MEM with 10% FBS, 1% P.S) for 24 h. Then different induction media (Cyagen, China) were used for adipogenic, osteogenic, and fibrogenic differentiation. The medium was changed every two days. In vitro adipogenic and osteogenic differentiation of LepR+ MSCs was performed following previous methods [36]. The experimental medium for fibroblast differentiation consisted ofα-MEM growth medium plus 100 ng/mL recombinant human connective tissue growth factor (R&D Biovender, USA) and 50 μg /mL ascorbic acid (Sigma-Aldrich).

Collection and analysis of related signatures

Twenty-six stemness gene sets were obtained from a web-based tool: StemChecker [37]. Six prostate stem cell-related gene sets were obtained from Yan et al. [38]. A total of 225 TGF-β related genes were identified from several common public databases, including "BIOCARTA_TGFB_PATHWAY", "KEGG_TGF_BETA_SIGNALING_PATHWAY" and "GO:0007179". The EMT signature, AR signature, and ER signature were obtained from MSigDB and included "HALLMARK EPITHELIAL MESENCHYMAL TRANSITION", "HALLMARK ANDROGEN RESPONSE", "HALLMARK ESTROGEN RESPONSE EARLY", and "HALLMARK ESTROGEN RESPONSE LATE". The relative scores of BPH samples were quantified by single-sample gene set enrichment analysis (ssGSEA) in the R package "gsva" [39]. Correlations were determined by Spearman’s correlation coefficient. Related signatures are detailed in Table S3.

Prediction of the therapeutic response

The drug sensitivity prediction for each patient based on bulk RNA-seq data was performed using the "oncoPredict" R package. The "oncoPredict" team has updated and uploaded the datasets required for fitting the ridge regression model, which includes resources from the Genomics of Drug Sensitivity in Cancer [40].

Molecular docking

The X-ray crystal structures of ROCK1 (PDB: 7JOU) were retrieved from the Protein Data Bank. The protonation state of all the compounds was set at pH = 7.4, and the compounds were expanded to 3D structures using Open Babel [41]. AutoDock Tools (ADT3) were applied to prepare and parametrize the receptor protein and ligands. The docking grid documents were generated by AutoGrid of sitemap, and AutoDock Vina (1.2.0) was used for docking simulation [42, 43]. The optimal pose was selected to analyze the interaction. Finally, the protein ligand interaction figure was generated by PyMOL. The ROCK1 protein is represented as a slate cartoon model, the ligand is shown as a cyan stick, and their binding sites are shown as magenta stick structures. Nonpolar hydrogen atoms are omitted. The hydrogen bonds, ionic interactions, and hydrophobic interactions are depicted as yellow, magenta and green dashed lines, respectively.

Statistical analysis

The data are presented as mean ± SEM or SD. Paired individual values were compared using unpaired tests. A Wilcoxon signed-rank test was employed for stemness and estimated IC50 comparison. For multiple comparisons, analysis of variance (ANOVA) with Bonferroni’s post hoc test was conducted where applicable. GraphPad Prism 9 software was utilized for statistical analysis. Statistical significance was defined as p < 0.05.

Results

Stromal hyperplasia and hyperactivation of TGF-β are important features of BPH

The progression of BPH is primarily triggered by increased stromal components and prostatic fibrosis. HE and Masson staining of BPH tissue revealed a notable increase in stromal components and collagen deposition (Fig. 1A-B). Moreover, vimentin expression was significantly elevated in the stroma of BPH tissue compared to normal prostate tissue (Fig. 1C-D). Aberrant activation of the TGF-β signaling pathway is a characteristic feature of the stromal microenvironment in BPH. This conclusion was validated through analysis of GEO datasets and immunohistochemistry, which demonstrated upregulation of TGF-β1 expression and downstream signaling in BPH (Fig. 1E-G). However, the precise biological role of TGF-β in the pathogenesis of BPH remains unclear.

Fig. 1
figure 1

Expression of active TGF-β and stromal accumulation in prostatic hyperplasia tissue. A HE staining of human normal prostate(left) and BPH (right) tissues. Scale bars = 50 μm. B Representative images of Masson trichrome staining of collagen deposition (blue) in prostate tissues. Scale bars = 20 μm. C-D Expression level of vimentin protein (brown) in BPH and normal prostate tissues. The results were expressed as mean optical density. Scale bars = 20 μm. E Expression of TGF-β1 mRNA between BPH and normal prostate tissues in GSE132714. F-G Expression level of p-Smad2/3 protein (brown) in BPH and normal prostate tissues. The results were expressed as mean optical density. Scale bars = 20 μm. H-I The Spearman correlation between the TGF-β score, stromal score and gland/stromal ratio. J-K GSEA of stromal fibrosis gene sets between high and low TGF-β score groups. Data represent means ± SEMs (n = 10 or 5 per group). **p < 0.01

Full size image

Numerous studies have demonstrated that TGF-β promotes stromal cell proliferation and induces EMT in epithelial cells [15, 16, 44]. To further investigate the potential association among TGF-β scores, stromal scores, and the gland/stromal cell ratio, we performed correlation analysis. The results revealed a strong positive and statistically significant correlation between the TGF-β score and stromal score (R = 0.761, Fig. 1H), as well as a negative correlation with the gland/stromal cell ratio (R = -0.362, F ig. 1I). However, the latter correlation was not significant.

Collagen deposition is an important feature of prostatic stromal hyperplasia. Gene set enrichment analysis (GSEA) indicated enhancement of pathways commonly associated with collagen, such as collagen formation and collagen biosynthesis and modifying enzyme pathways, in the high TGF-β score group (Fig. 1J-K). These findings suggest that aberrant activation of TGF-β signaling and stromal hyperplasia are not only important features of BPH but also indicate a potential significant relationship between these factors. However, the underlying mechanism of this association is unknown.

Given the significant role of TGF-β responses in prostatic stromal hyperplasia, we established a PE-induced mouse model following established protocols [30]. As depicted in Figure S1A, the mouse prostate index [calculated as prostate weight (mg) divided by body weight (g)] exhibited a significant 1.2-fold increase in the group of mice receiving subcutaneous injections of PE. Histological examination of HE and Masson staining prostate sections from the PE-induced mice revealed evident stromal compartment hyperplasia and papillary accumulation of epithelial cells compared to those of the saline-treated mice after 4 weeks of injection (Fig. S1B-C). Consistent with expectations, there was a significant increase in the number of vimentin+ fibroblasts in the prostate stroma, and immunostaining for p-Smad2/3 revealed upregulated expression of p-Smad2/3 in both epithelial and stromal cells following continuous PE injection for 4 weeks (Fig. S1D-E).

TGF-β in BPH patients associated with stemness

Stromal reawakening is one of the most important theories in the pathogenesis of BPH [11]. Supporting evidence for this theory includes the presence of MSCs in human BPH tissue [28]. Hence, evaluation of the stemness of each BPH sample using the ssGSEA algorithm based on the stemness gene set is theoretically feasible. This investigation revealed that the group with the high TGF-β score exhibited a higher stemness index, which is consistent with the involvement of TGF-β superfamily signaling pathways in early developmental events such as embryonic patterning and cell fate determination. Most of the stemness indices showed significant differences between the high and low TGF-β groups (Fig. 2A). Interestingly, four prostatic stemness indices did not display significant differences between the two groups, indicating that stem cells originating from outside the prostate may play a crucial role in the pathogenesis of BPH rather than prostate stem cells (Fig. 2B).

Fig. 2
figure 2

Stemness was correlated with different TGF-β scores in BPH patients. A Heatmap depicting the landscape of the ssGSEA stemness index in high or low TGF-β score groups. B Boxplot displaying the 26 ssGSEA stemness index between two groups by Wilcoxon rank sum test. C The correlation between the TGF-β score and stemness index. Each column represents a stemness gene set. D The correlation between stromal score and stemness index. Each column represents a stemness gene set. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

Subsequently, we investigated the relationships between the stemness index and the TGF-β score and stromal score. The stemness index exhibited positive associations with both the TGF-β score and stromal score in GSE132714, further validating the strong correlation between the TGF-β score and stemness index in the GSE101486 dataset. (Fig. 2C-D, Fig. S2A). Notably, a positive association was primarily observed for the transition zone volume and one specific stemness index (Fig. S2B). Overall, these findings demonstrate a strong correlation between the abnormal activation of TGF-β, the stemness index, and the stromal score in BPH. Moreover, increased stemness may contribute to the benign volume enlargement observed in the transitional zone of the prostate.

Circulating LepR+ MSCs recruited to the reactive stroma acquire fibrotic phenotypes

Victor K’s investigation had identified a population of multipotent stem cells coexisting in human prostate stromal tissue, and our previous study further demonstrated that nestin+ MSCs were recruited by TGF-β in prostatic stromal hyperplasia [30, 45]. To further validate the findings regarding TGF-β and MSCs, we conducted GSEA in the high TGF-β score group compared to the low TGF-β score group. As anticipated, pathway enrichment analysis revealed that the enriched genes were primarily involved in the transcriptional regulation of pluripotent stem cell pathways, embryonic stem cell pluripotency pathways, and pluripotent stem cell differentiation pathways (Fig. 3A-B). In addition, MSC migration-related pathways were significantly enriched in the high TGF-β score group (Fig. 3C).

Fig. 3
figure 3

LepR+ cells are responsible for generating fibroblasts/myofibroblasts at the remodeling sites of the reawakening stroma. A-B GSEA of stem cell-related gene sets between the high and low TGF-β score groups. C GSEA of MSC migration related-pathway gene sets between the high and low TGF-β score groups. D CD45– and tdTomato+ prostatic cells were sorted by flow cytometry for fibrogenic (E), lipogenic (F), osteogenic (G) induction. Scale bar = 10 μm. H-I Flow cytometry was used to measure the percentage of CD45–, and tdTomato+ cells in the blood of the two groups. J-K Immunofluorescence analysis of ventral prostate tissue sections from 12-week-old LepR-tdTomato mice treated with saline or PE. Scale bar = 50 μm. L Double immunofluorescence (CD140a, green; tdTomato, red) analysis of ventral prostate tissues from LepR-tdTomato mice treated with phenylephrine. Scale bar = 20 μm. M–N Double immunofluorescence (α-SMA or vimentin, green; tdTomato, red) analysis of ventral prostate tissues from LepR-tdTomato mice treated with PE. Scale bar = 20 or 50 μm. Data represent means ± SEMs (n = 5 per group). *p < 0.05, **p < 0.01

Full size image

Since LepR+ MSCs were identified as the main source of myofibroblasts in primary myelofibrosis, further investigations are feasible to determine whether LepR+ mesenchymal/stromal stem cells are recruited and differentiate into myofibroblasts or fibroblasts in prostatic stromal hyperplasia [46]. To address this issue, we crossed tdTomatoflox/flox mice with transgenic mice expressing an improved Cre recombinase under the control of the leptin receptor gene promoter (LepR-cre). Our PCR analysis confirmed the genotype of the LepR-tdTomato mice (Fig. S3A). Subsequent studies confirmed the multilineage differentiation potential of LepR+ cells, which were isolated and sorted based on their CD45-negative and tdTomato+ fluorescence (Fig. 3D). Their multipotency was assessed through fibrogenesis, osteogenesis, and adipogenesis assays (Fig. 3E-G).

Furthermore, LepR-tdTomato mice were utilized to investigate whether aberrant activation of TGF-β is involved in the recruitment of LepR+ MSCs during prostatic hyperplasia. The population of CD45−tdTomato+ cells in peripheral blood nearly doubled after PE injection compared to the control (Fig. 3H-I), and tdTomato+ cells also significantly increased in the prostate stroma of the PE-induced mice (Fig. 3J-K). Immunostaining of CD140a, a marker for LepR+ MSCs, displayed colocalization with tdTomato in the prostate stroma, as shown in Fig. 3L. Subsequent studies explored the role of LepR+ MSCs in prostatic stromal hyperplasia. Immunofluorescence staining of α-SMA and vimentin in prostate sections partially revealed the origin of prostate stromal cells. α-SMA staining demonstrated that smooth muscle cells were primarily derived from LepR+ cells (Fig. 3M), while vimentin staining also indicated that LepR+ cells contributed to the formation of prostatic stromal fibroblasts/myofibroblasts (Fig. 3N). These findings highlight the importance of LepR+ cells as an important source of stromal cells in the prostate.

Enhanced ROCK1 expression is crucial for the migration and differentiation of LepR+ MSCs

The molecular mechanisms of TGF-β in BPH are not fully understood, although the principal components of the canonical and noncanonical TGF-β signaling pathways have been identified. GSEA between the high and low TGF-β groups revealed that pathways enriched in the high TGF-β group included the RhoA pathway, Rho GTPase cycle and Rho GTPases activate ROCKs (Fig. 4A). In this context, we investigated the association between TGF-β and RhoA, a member of the small G-proteins belonging to the Rho GTPase family and activated by TGF-β-dependent pathways. We replicated the association between TGF-β and RhoA in GTEx prostate samples (Fig. 4B, R = 0.8). ROCK1 and ROCK2 are key downstream molecules of RhoA signaling, and the Pearson correlation coefficients between ROCK1 or ROCK2 and TGF-β receptors were 0.73 and 0.65, indicating a strong relationship (Fig. 4C, Fig. S3B).

Fig. 4
figure 4

TGF-β mediates overactivated RhoA/ROCK1 signaling in BPH. A GSEA of RhoA pathway gene sets between high and low TGF-β score groups. B The Spearmen correlation of RhoA a and TGFBR1, TGFBR2 in normal prostate. C The Spearmen correlation of ROCK1 and TGFBR1, TGFBR2 in normal prostate. D ROCK1 and ROCK2 expression was determined by RT–qPCR. E–F Immunoblot analysis of ROCK1, in normal prostate (control) and BPH. G Expression of active RhoA (red) in human normal prostate(left) and BPH (right) tissues. Scale bars = 50 μm. H Expression of ROCK1 (red) in prostate tissues. Scale bars = 50 μm. I-J Double immunofluorescence (ROCK1, green; tdTomato, red) analysis of ventral prostate sections from LepR-tdTomato mice treated with or without PE. White arrows indicate double positive signals; Scale bars = 20 μm or 10 μm. Data represent means ± SDs (n = 5 per group). *p < 0.05

Full size image

Additionally, to further investigate the mechanism, we collected clinical specimens of normal prostate (control) and BPH and evaluated the expression levels of ROCK1 and ROCK2. RT–qPCR and immunoblotting analysis showed increased expression of ROCK1, but not ROCK2, in BPH (Fig. 4D-F). Further verification focused on ROCK1, and immunofluorescence staining confirmed enhanced expression of RhoA and ROCK1 in prostate sections from BPH patients with positive signals primarily distributed around the glands (Fig. 4G-J). The correlation analysis also revealed a strong association between ROCK1 expression and stemness of BPH tissues (Fig. S3C). Dual immunofluorescence staining demonstrated overactivation of ROCK1 in LepR+ MSCs within the prostate stroma of the PE-induced mice (Fig. 4I-J). This distribution of ROCK1 signals correlated with the previous finding (Fig. 3N-M) that LepR+ cells are also distributed around the glands. These results suggest that ROCK1 activation in LepR+ cells may be a critical signaling event in the TGF-β pathway in BPH. While multiple studies have demonstrated that ROCK1 plays a crucial role in cellular migration and transdifferentiation through cytoskeletal remodeling and modulation of adhesion, its role in the migration and differentiation of LepR+ MSCs is poorly understood. To validate the role of ROCK1, we synthesized three siRNAs targeting ROCK1. The knockdown efficiency in LepR+ cells was confirmed by RT–qPCR and Western blot analysis (Fig. S4A-B). In the Transwell assay, the cell count of the ROCK1 knockdown group was significantly decreased compared to the mock group after 24 h of cell inoculation (Fig. 5A-B). In the scratch wound healing assay, the cell migration ability was reduced in the ROCK knockdown group compared to the control group (Fig. 5C-D). These results demonstrate that ROCK1 is a crucial molecular regulator of the migration of LepR+ MSCs.

Fig. 5
figure 5

ROCK1 Regulates LepR+ cell mobilization and differentiation in vitro. A-D Transwell and wound healing assays were performed to detect LepR+ MSCs treated with TGF-β + siROCK1 alone or simultaneously. Scale bar = 100 μm. E–F GSEA of PI3K-AKT or FAK pathway gene sets between the high and low TGF-β score groups. G-J Immunoblot analysis of PI3K, p-PI3K, FAK, p-FAK, AKT, p-AKT, Cola1, α-SMA, vimentin in differently prepared MSC lysates (PI3K inhibitor, LY294002, 10 μM; ROCK1 inhibitor, GSK269962A, 1 μM). β-actin: loading control. Data represent the means ± SEMs (n = 3 per group). **p < 0.01, ***p < 0.001

Full size image

To analyze the pathways involved in LepR+ MSCs migration, we performed GSEA using the GSEA tool and MSigDB databases. The analysis revealed the involvement of the ‘Pluripotent Stem Cell Differentiation,’ ‘PI3K-AKT,’ and ‘FAK’ pathways (Fig. 4B and Fig. 5E-F), which have been reported to be important for the migration and differentiation of MSCs through ROCK1. Based on this finding, we hypothesized that ROCK1 and these pathways play similar roles in LepR+ MSCs, which we further investigated experimentally. We examined whether blocking the TGF-β-induced increase in ROCK1 through ROCK1-specific siRNA transfection into LepR+ MSCs changed the status of the PI3K/AKT/FAK pathway. A mock siRNA was used as a control. The p-PI3K protein level significantly decreased in the TGF-β-treated LepR+ MSCs following ROCK1 siRNA treatment for 48 h, whereas this decrease was not observed in the mock siRNA-treated cells (Fig. 5G). Phosphorylated of AKT (p-AKT S473) and FAK (p-FAK Tyr397), which are known to regulate cellular functions such as proliferation, apoptosis, and migration through the PI3K/AKT pathway, decreased following ROCK1 knockdown in the TGF-β-treated LepR+ MSCs. Furthermore, this phosphorylation was inhibited by treatment with LY294002, a broad-spectrum PI3K inhibitor (Fig. 5H).

Profibrotic mediators, including TGF-β, thrombin, and lysophosphatidic acid, act through receptors that activate ROCK1. Inhibition of ROCK1 activation could be a potent therapeutic strategy for fibrosis-related diseases. We demonstrated that silencing ROCK1 in the LepR+ MSCs resulted in decreased fibrosis, as evidenced by reduced expression levels of col1a1, vimentin, and α-SMA, compared to those of the mock siRNA-treated cells (Fig. 5I, Fig. S4F-H). Additionally, treatment with GSK269962A, a selective ROCK inhibitor, effectively inhibited mesenchymal differentiation, as indicated by low levels of Col1a1, vimentin, and α-SMA (Fig. 5J). These findings suggest that ROCK1 affects the migration and differentiation of LepR+ MSCs and could be a potential target for fibrosis-related diseases.

Knockdown of ROCK1 signaling ameliorates prostatic stromal hyperplasia

To validate the role of ROCK1 in the mobilization and differentiation of LepR+ MSCs and prostate stromal formation in vivo, we conducted heterochronic parabiosis experiments. We joined the vasculature of Lepr-tdTomato mice (carrying the tdTomato marker in LepR+ cells) with wild-type mice (Fig. 6A-B). All parabiotic pairs were treated with PE, a compound used to induce prostatic hyperplasia. We injected siRNAs targeting ROCK1 or an equal negative control siRNA (NC) into the cojoined wild-type mice.

Fig. 6
figure 6

Inhibition of ROCK1 signaling inhibits LepR+ cells mobilization and differentiation in vivo. A Schematic diagram of the experimental strategy. B Strategies and intervention for conjoined twin mice. C The proportion of CD45– and tdTomato+ cells in the peripheral blood of WT (wild-type) mice detected by flow cytometry. D-E Double immunofluorescence (α-SMA or vimentin, purple; tdTomato, red) analysis of ventral prostate sections from WT mice treated with siROCK1 or Mock. F Representative images of Masson trichrome staining of collagen deposition in WT mice ventral prostate sections. Scale bars = 20 μm. G Statistical analysis of flow cytometry detection. H Statistical analysis of tdTomato+ cells in WT mice prostate tissues. I Statistical analysis of collagen deposition in WT mice ventral prostate sections. Data represent the means ± SDs (n = 3 per group). *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

Flow cytometry analysis of peripheral blood revealed that treatment with ROCK1 siRNA reduced the proportion of tdTomato+ CD45− cells in the circulation (Fig. 6C and G). Furthermore, treatment with ROCK1 siRNA dramatically decreased the presence of tdTomato+–labeled α-SMA+ or vimentin+ fibroblast/myofibroblast cells and collagen deposition in the prostate stromal tissue of PE-treated cojoined wild-type mice compared to the mice treated with the NC siRNA (Fig. 6D-F, H- I). These in vivo and in vitro ROCK1 knockdown data confirmed that reduced ROCK1 signaling inhibits the recruitment and differentiation of LepR+ cells in prostatic hyperplasia. The results provide further evidence for the critical role of ROCK1 in the migration and differentiation of LepR+ MSCs and its involvement in the formation of prostate stromal tissue.

Potential therapeutic options for hyperactivation of ROCK1 signaling in BPH

To further elucidate the therapeutic potential of ROCK inhibitors in TGF-β-overactive BPH, we examined the enrichment of ROCK1 signaling pathways using GSEA. We found a significant negative enrichment of genes upregulated by the ROCK1 inhibitor in normal prostate tissue (Fig. 7A). This finding suggests that ROCK1 inhibitors might counteract the overactive ROCK1 signaling observed in BPH. Then, we evaluated and observed the differences in sensitivity to 198 common drugs in BPH patients between the two groups. To further screen the ROCK1 inhibitors for prostatic hyperplasia, drug sensitivities were predicted and differences in drug sensitivities between the high- and low-stemness samples were analyzed. The results showed that patients in the high stemness group were more sensitive to the ROCK1 inhibitors GSK269962A and AT1314, implying that these drugs have better therapeutic effects in the overactivation of TGF-β/ROCK1 in BPH. (Fig. 7B, C). Additionally, we specifically focused on GSK2966692A, a known ROCK inhibitor with anti-fibrotic properties. Correlation analysis showed that the IC50 was negatively correlated with the expression of ROCK1 (Fig. 7D). In silico studies and molecular docking revealed the formation of multiple hydrogen bonds between GSK2966692A and key residues of ROCK1, such as Glu154 and LYS105. The binding energy of the protein–ligand complex was -10.1 kcal/mol, indicating a strong interaction (Fig. 7E). These results provide a good reference for clinical medication.

Fig. 7
figure 7

GSK269962A targeting ROCK1 attenuates prostatic stromal hyperplasia. A GSEA of ROCK-related signatures in the high TGF-β score group, showing that genes upregulated by ROCK inhibitors are negatively enriched compared to those of the control samples. B-C ROCK1 inhibitor prediction of the high stemness groups. D Correlation analysis of the IC50 of GSK269962A and ROCK1 expression. E Molecular docking simulation of GSK269962A and ROCK1. F HE staining of ventral prostate sections from PE-, PE + solvent- or PE + GSK269962A treated mice. Scale bars = 20 μm. G Prostate index of mice treated with PE, PE + solvent or PE + GSK269962A. H-I Representative images of Masson trichrome staining of collagen deposition on ventral prostate sections and statistical analysis. Pictures were taken at two magnifications: × 200 (upper panels) and × 400 (lower panels). Scale bars = 20 μm. J-K Vimentin immunofluorescence staining and statistical analysis. Scale bars = 20 μm. Data represent the means ± SEMs (n = 5 per group). *p < 0.05, ***p < 0.001

Full size image

To further validate the therapeutic efficacy of GSK2966692A, we conducted animal studies. Histological examination using HE and Masson’s staining demonstrated a reduction in the interstitial component and collagen deposition in the prostates of the mice treated with GSK2966692A. This reduction was consistent with the decreased prostate index observed in the treated group (Fig. 7F-I). Immunofluorescence analysis of prostate sections from the GSK2966692A-treated mice confirmed a significant decrease in vimentin+ fibroblasts/myofibroblasts cells compared to those of the group treated with the solvent (Fig. 7J-K). Overall, our combined analyses and experimental results indicate that GSK2966692A is a potential drug for the treatment of prostatic stromal hyperplasia in BPH. Its ability to inhibit ROCK1 signaling and reduce fibrosis-related features suggests that this drug could be a valuable therapeutic option for TGF-β/ROCK1-overactive BPH.

Discussion

The theory of embryonic reawakening, proposed by McNeal in 1976, has become an important concept in the pathogenesis of BPH [11, 47]. However, debate is still ongoing, and direct evidence linking embryonic reawakening to the occurrence of BPH is lacking [7]. The initial theory suggests that restricted growth in the distal transition zone plays a significant role in embryonic reawakening in BPH [14]. Recent advancements in immunohistochemical techniques, lineage tracing, and flow cytometry have revealed the presence of multipotent stem cells and stem cell-like stromal cells in the transition zone of BPH. Lin et al. reported that primary stromal cells from BPH patients possess MSC markers, strong proliferative potential, and the ability to differentiate or transdifferentiate into myogenic, adipogenic, and osteogenic lineages. Brennen et al. showed that MSCs represent 0.01–1.1% of the total cells present in core biopsies of primary human prostatectomies. MSCs in these prostatectomy samples are positive for FAP, CD90, CD73, and CD105 and negative for hematopoietic lineage markers [48]. Therefore, Brennen's hypothesis innovatively proposes infiltrating MSCs as the driver of occurrence in BPH [14]. Previous study clarified that the primary reservoir of LepR+ cells is in the adult bone marrow and confirmed the involvement of LepR+ MSCs in embryonic and postnatal bone growth [49, 50]. The recruitment mechanism of LepR+ cells is currently unclear, but there are reports in the literature that PDGFα, IGF-1, MCP-1, and CXCL12/CXCR4 are involved in the recruitment of MSCs; whether the recruitment of LepR + cells involve these molecules requires further study [51]. In fact, active TGF-β released from inflammatory or injured tissues recruits MSCs for tissue repair/remodeling. The continuous exposure of transition zone tissue to urinary components and an inflammatory microenvironment generated by self-antigens can recruit bone marrow-derived MSCs and induce stromal proliferation through paracrine signaling, leading to nodular growth of the prostate. TGF-β also emerged as an important cytokine recruiting MSCs, inducing prostate stromal hyperplasia [14, 52]. In this study, we demonstrated significant activation of the TGF-β/ROCK1 pathway, which is associated with embryonic development, in BPH tissues. For the first time, we quantified the stemness of BPH tissues using ssGSEA and found a strong positive correlation between the stemness of BPH tissues and the TGF-β pathway score, revealing that BPH tissues with high TGF-β scores may have a greater degree of stemness, as they can recruit multipotential MSCs to the prostate, providing direct validation of the relationship between BPH tissue stemness and TGF-β. This finding provides robust evidence supporting the theory of embryonic reawakening in the pathogenic mechanisms of BPH.

The TGF-β superfamily is known to regulate various cellular functions, including EMT, fibrosis, cellular immunity, proliferation, apoptosis, and dedifferentiation. The correlation analysis in this study confirmed this positive relationship between TGF-β and EMT and fibrosis (Fig. S2C). The immunoscore represents the level of immune cell infiltration in the tissue, but more research is needed to understand the relationship between the TGF-β pathway score and immunoscore in BPH (Fig. S2D) Excessive activation of the TGF-β pathway has been identified as an important molecular driver in BPH. Targeting excessive activation of TGF-β could serve as a potential therapeutic strategy for BPH. Several TGF-β inhibitors are currently undergoing clinical trials or are in clinical use for various diseases. For instance, fresolimumab, a human anti-TGF-β monoclonal antibody, has demonstrated efficacy against melanoma and renal cell activity in clinical trials, while pirfenidone can directly inhibit TGF-β production and alleviate pulmonary fibrosis [53, 54]. Investigating changes in prostate volume and IPSS scores in these subjects may yield novel insights into BPH treatment. The imbalance in androgen and estrogen levels with increasing age in prostate tissue also contributes to BPH progression. Elevated levels of estrogen in the prostate tissue promote hyperplastic growth and abnormal tissue remodeling in BPH [55,56,57]. Interestingly, the profibrotic effects of TGF-β are similar to those of estrogen, and bioinformatic analysis showed a strong positive correlation between the TGF-β pathway score and the estrogen receptor (ER) score, while the androgen receptor (AR) score did not appear to be associated with TGF-β (Fig. S2E-F). Further research is needed to explore this association in more detail.

Although we have shown through bioinformatic analysis, lineage tracing, and a parabiosis mouse model that aberrant TGF-β/ROCK1 signaling correlates to some extent with prostate stemness, the association was confirmed only in prostate stroma and not in epithelial tissues. Many recent studies have found that epithelial stem cells play an essential role in the development, progression, and therapeutic resistance of BPH [13, 58]. Wang et al. also identified Zeb1+ prostate epithelial cells, which are multipotent prostate basal stem cells capable of self-renewal and generating functional prostatic glandular structures at the single-cell level [59]. Using single-cell sequencing technology, the Strand lab identified a new type of epithelial cell from the donor's prostate, namely "club" cells [60]. Further studies clarified the stem-like and castration-insensitive properties of these cells [61]. SCGB1A1 and SCGB3A1 are considered characteristic marker genes of club cells. Interestingly, the expression of both characteristic marker genes increased in high TGF-β samples, an observation worthy of further investigation (Fig. S3D).

The enlargement of the transition zone volume is an important characteristic of BPH progression [1]. This study found a positive correlation between the stemness index represented by multiple stemness gene sets and the transition zone volume (although only the Hs_SC_Shats gene set showed a significant positive correlation) (Fig. S2B). This finding is consistent with the report by Yan et al., indicating higher expression of stemness genes in the transition zone of the prostate [38]. In this study, the stemness index of most gene sets showed a negative correlation with the immunoscore, although only two correlations were statistically significant (Fig. S3E, red font). This observation suggests that BPH with higher stemness may exhibit lower levels of immune cell infiltration, which seems contradictory to the recruitment of MSCs in an inflammatory microenvironment.

Accumulating evidence suggests a crucial role for the ROCKs system in the pathogenesis of various urogenital disorders [62]. ROCKs, as serine/threonine kinases, are essential contributors to the regulation of the cytoskeleton [63]. Prostate fibrosis, characterized by the replacement of normal tissue with noncompliant fibrotic tissue, is associated with ROCK-mediated processes [64]. While ROCK1 appears more crucial in mediating fibrosis, ROCK2 also contributes to this phenomenon [65]. In addition, ROCK1-mediated EMT in prostatic epithelium exacerbates the accumulation of mesenchymal-like cells [66]. The role of ROCK in MSCs remains largely unknown, although studies suggest that ROCK inhibitors, such as Fasudil and Y27632, influence MSC differentiation [25, 67]. This research confirmed the role of ROCK1 signaling in regulating the migration and differentiation of MSCs, as well as its involvement in remodeling the prostate stroma. ROCK1 mediates MSC migration, at least in part, through the PI3K/AKT/FAK pathway.

Considering the implication of the ROCK molecule in BPH, its inhibitors present potential therapeutic agents. GSK269962A, a ROCK inhibitor, has demonstrated efficacy in alleviating cyclophosphamide-induced detrusor overactivity and bladder inflammation [68, 69]. Our research affirms the effectiveness of the small molecule inhibitor GSK269962A in mitigating interstitial prostatic hyperplasia. Pan et al. conducted analyses on potential cytotoxic side effects of GSK269962A in C57BL/6 mice, revealing no overt harmful effects on vital organs or the hematological system, and other study suggest that some side effects of GSK269962A were hypotension and cardiovascular collapse [70, 71]. However, we cannot quantify the side effects of GSK269962A due to the limited experimental conditions.

In summary, this study provides evidence supporting the theory of embryonic reawakening in BPH. The results demonstrate a positive correlation between the TGF-β pathway score, stromal score, and stemness index in BPH tissues. The study also highlights the role of TGF-β in EMT, its potential interaction with estrogen signaling, and its influence on immune homeostasis. Furthermore, we elucidate the involvement of ROCK1 signaling in BPH pathogenesis and suggest the potential of the ROCK1 inhibitor GSK269962A as a therapeutic option.

Availability of data and materials

No datasets were generated or analysed during the current study.

Abbreviations

TGF-β:

Transforming growth factor-β

ROCK1:

Rho-associated protein kinase 1

BPH:

Benign prostatic hyperplasia

LepR:

Leptin receptor

LUTS:

Lower urinary tract symptoms

MSCs:

Mesenchymal stem cells

EMT:

Epithelial-mesenchymal transition

PE:

Phenylephrine

HE:

Hematoxylin and Eosin

OCT:

Optimal cutting temperature compound

IOD:

Integral optical density

BSA:

Bovine serum albumin

PBS:

Phosphate-buffered saline

RT–qPCR:

Real‐time quantitative PCR

GAPDH:

Glyceraldehyde-3-phosphate dehydrogenase

PS:

Penicillin-streptomycin

ssGSEA:

single-sample gene set enrichment analysis

GEO:

Gene expression omnibus

GTEx:

Genotype-tissue expression

ROCK2:

Rho-associated protein kinase 2

α-SMA:

Alpha-smooth muscle actin

siRNA:

Small interfering RNA

Glu:

Glutamic acid

LYS:

Lysine

FAP:

Fibroblast activation protein

SCGB1A1:

Secretoglobin family 1A member 1

SCGB3A1:

Secretoglobin family 3A member 1

References

  1. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031.

    Article  PubMed  Google Scholar 

  2. Zhu C, Wang DQ, Zi H, Huang Q, Gu JM, Li LY, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res. 2021;8(1):64.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Liu D, Li C, Li Y, Zhou L, Li J, Wang Y, et al. Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019. World J Urol. 2023;41(12):3629–34.

    Article  PubMed  Google Scholar 

  4. Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020;117(49):843–54.

    PubMed  PubMed Central  Google Scholar 

  5. Ng M, Baradhi KM. Benign prostatic hyperplasia. In: StatPearls (Eds.), StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC. Treasure Island: Ineligible companies. Disclosure: Krishna Baradhi declares no relevant financial relationships with ineligible companies. 2023.

  6. Kang TW, Jung JH, Hwang EC, Borofsky M, Kim MH, Dahm P. Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2020;3(3):Cd013251.

    PubMed  Google Scholar 

  7. Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia - what do we know? BJU Int. 2021;127(4):389–99.

    Article  CAS  PubMed  Google Scholar 

  8. Welén K, Damber JE. Androgens, aging, and prostate health. Rev Endocr Metab Disord. 2022;23(6):1221–31.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cunha GR, Vezina CM, Isaacson D, Ricke WA, Timms BG, Cao M, et al. Development of the human prostate. Differentiation. 2018;103:24–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Timms BG, Hofkamp LE. Prostate development and growth in benign prostatic hyperplasia. Differentiation. 2011;82(4–5):173–83.

    Article  CAS  PubMed  Google Scholar 

  11. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978;15(4):340–5.

    CAS  PubMed  Google Scholar 

  12. Bierhoff E, Walljasper U, Hofmann D, Vogel J, Wernert N, Pfeifer U. Morphological analogies of fetal prostate stroma and stromal nodules in BPH. Prostate. 1997;31(4):234–40.

    Article  CAS  PubMed  Google Scholar 

  13. Joseph DB, Turco AE, Vezina CM, Strand DW. Progenitors in prostate development and disease. Dev Biol. 2021;473:50–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Brennen WN, Isaacs JT. Mesenchymal stem cells and the embryonic reawakening theory of BPH. Nat Rev Urol. 2018;15(11):703–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Alonso-Magdalena P, Brössner C, Reiner A, Cheng G, Sugiyama N, Warner M, et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci U S A. 2009;106(8):2859–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hennenberg M, Schreiber A, Ciotkowska A, Rutz B, Waidelich R, Strittmatter F, et al. Cooperative effects of EGF, FGF, and TGF-β1 in prostate stromal cells are different from responses to single growth factors. Life Sci. 2015;123:18–24.

    Article  CAS  PubMed  Google Scholar 

  17. Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, Berger P. Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Ageing Dev. 2005;126(1):59–69.

    Article  CAS  PubMed  Google Scholar 

  18. La Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE. Endocrine control of benign prostatic hyperplasia. Andrology. 2016;4(3):404–11.

    Article  PubMed  Google Scholar 

  19. Descazeaud A, Weinbreck N, Robert G, Vacherot F, Abbou CC, Labrousse F, et al. Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int. 2011;108(2 Pt 2):E23-28.

    PubMed  Google Scholar 

  20. Wegner KA, Mueller BR, Unterberger CJ, Avila EJ, Ruetten H, Turco AE, et al. Prostate epithelial-specific expression of activated PI3K drives stromal collagen production and accumulation. J Pathol. 2020;250(2):231–42.

    Article  CAS  PubMed  Google Scholar 

  21. Liu S, Ren J, Ten Dijke P. Targeting TGFβ signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19(1):128–39.

    Article  CAS  PubMed  Google Scholar 

  23. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247–69.

    Article  CAS  PubMed  Google Scholar 

  24. Kilian LS, Voran J, Frank D, Rangrez AY. RhoA: a dubious molecule in cardiac pathophysiology. J Biomed Sci. 2021;28(1):33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ke X, Do DC, Li C, Zhao Y, Kollarik M, Fu Q, et al. Ras homolog family member A/Rho-associated protein kinase 1 signaling modulates lineage commitment of mesenchymal stem cells in asthmatic patients through lymphoid enhancer-binding factor 1. J Allergy Clin Immunol. 2019;143(4):1560-1574.e1566.

    Article  CAS  PubMed  Google Scholar 

  26. Duan ZW, Lu H. Effect of mechanical strain on cells involved in fracture healing. Orthop Surg. 2021;13(2):369–75.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Li Y, Tai HC, Sladojevic N, Kim HH, Liao JK. Vascular stiffening mediated by rho-associated coiled-coil containing kinase isoforms. J Am Heart Assoc. 2021;10(20):e022568.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Brennen WN, Kisteman LN, Isaacs JT. Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. Prostate. 2016;76(6):552–64.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kwon OJ, Zhang Y, Li Y, Wei X, Zhang L, Chen R, et al. Functional heterogeneity of mouse prostate stromal cells revealed by single-cell RNA-Seq. iScience. 2019;13:328–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wang L, Xie L, Tintani F, Xie H, Li C, Cui Z, et al. Aberrant transforming growth factor-β activation recruits mesenchymal stem cells during prostatic hyperplasia. Stem Cells Transl Med. 2017;6(2):394–404.

    Article  CAS  PubMed  Google Scholar 

  31. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell. 2014;15(2):154–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Zheng H, Xie J, Song K, Yang J, Xiao H, Zhang J, et al. StemSC: a cross-dataset human stemness index for single-cell samples. Stem Cell Res Ther. 2022;13(1):115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Chen Q, Gu M, Cai ZK, Zhao H, Sun SC, Liu C, et al. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44. Cell Mol Life Sci. 2021;78(3):949–62.

    Article  CAS  PubMed  Google Scholar 

  34. Chen Z, Chen Y, Li Y, Lian W, Zheng K, Zhang Y, et al. Prrx1 promotes stemness and angiogenesis via activating TGF-β/smad pathway and upregulating proangiogenic factors in glioma. Cell Death Dis. 2021;12(6):615.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kamran P, Sereti KI, Zhao P, Ali SR, Weissman IL, Ardehali R. Parabiosis in mice: a detailed protocol. J Vis Exp. 2013;(80):5056.

  36. Cao J, Jin L, Yan ZQ, Wang XK, Li YY, Wang Z, et al. Reassessing endothelial-to-mesenchymal transition in mouse bone marrow: insights from lineage tracing models. Nat Commun. 2023;14(1):8461.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Pinto JP, Kalathur RK, Oliveira DV, Barata T, Machado RS, Machado S, et al. StemChecker: a web-based tool to discover and explore stemness signatures in gene sets. Nucleic Acids Res. 2015;43(W1):W72-77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yan Q, Wang M, Xia H, Dai C, Diao T, Wang Y, et al. Single-cell RNA-sequencing technology demonstrates the heterogeneity between aged prostate peripheral and transitional zone. Clin Transl Med. 2022;12(10):e1084.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.

  41. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J Cheminform. 2011;3:33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inf Model. 2021;61(8):3891–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. He Y, Ou Z, Chen X, Zu X, Liu L, Li Y, et al. LPS/TLR4 signaling enhances TGF-β response through downregulating BAMBI during prostatic hyperplasia. Sci Rep. 2016;6:27051.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lin VK, Wang SY, Vazquez DV, Xu CC, Zhang S, Tang L. Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property. Prostate. 2007;67(12):1265–76.

    Article  CAS  PubMed  Google Scholar 

  46. Sarkaria SM, Zhou J, Bao S, Zhao W, Fang Y, Que J, et al. Systematic dissection of coordinated stromal remodeling identifies Sox10(+) glial cells as a therapeutic target in myelofibrosis. Cell Stem Cell. 2023;30(6):832-850.e836.

    Article  CAS  PubMed  Google Scholar 

  47. Cunha GR, Ricke WA. A historical perspective on the role of stroma in the pathogenesis of benign prostatic hyperplasia. Differentiation. 2011;82(4–5):168–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 2013;4(1):106–17.

    Article  PubMed  Google Scholar 

  49. Yen YT, Chien M, Wu PY, Hung SC. PP2A in LepR+ mesenchymal stem cells contributes to embryonic and postnatal endochondral ossification through Runx2 dephosphorylation. Commun Biol. 2021;4(1):658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Shu HS, Liu YL, Tang XT, Zhang XS, Zhou B, Zou W, et al. Tracing the skeletal progenitor transition during postnatal bone formation. Cell Stem Cell. 2021;28(12):2122-2136.e2123.

    Article  CAS  PubMed  Google Scholar 

  51. Pajarinen J, Lin T, Gibon E, Kohno Y, Maruyama M, Nathan K, et al. Mesenchymal stem cell-macrophage crosstalk and bone healing. Biomaterials. 2019;196:80–9.

    Article  CAS  PubMed  Google Scholar 

  52. Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer. 2013;20(5):R269-290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE. 2014;9(3):e90353.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–57.

    Article  CAS  PubMed  Google Scholar 

  55. Ho CK, Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol. 2011;8(1):29–41.

    Article  CAS  PubMed  Google Scholar 

  56. Farnsworth WE. Roles of estrogen and SHBG in prostate physiology. Prostate. 1996;28(1):17–23.

    Article  CAS  PubMed  Google Scholar 

  57. Hammes SR, Levin ER. Impact of estrogens in males and androgens in females. J Clin Invest. 2019;129(5):1818–26.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Guo W, Li L, He J, Liu Z, Han M, Li F, et al. Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. Nat Genet. 2020;52(9):908–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Wang X, Xu H, Cheng C, Ji Z, Zhao H, Sheng Y, et al. Identification of a Zeb1 expressing basal stem cell subpopulation in the prostate. Nat Commun. 2020;11(1):706.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Henry GH, Malewska A, Joseph DB, Malladi VS, Lee J, Torrealba J, et al. A cellular anatomy of the normal adult human prostate and prostatic urethra. Cell Rep. 2018;25(12):3530-3542.e3535.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Joseph DB, Henry GH, Malewska A, Iqbal NS, Ruetten HM, Turco AE, et al. Urethral luminal epithelia are castration-insensitive cells of the proximal prostate. Prostate. 2020;80(11):872–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Gur S, Kadowitz PJ, Hellstrom WJ. RhoA/Rho-kinase as a therapeutic target for the male urogenital tract. J Sex Med. 2011;8(3):675–87.

    Article  CAS  PubMed  Google Scholar 

  63. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4(6):446–56.

    Article  CAS  PubMed  Google Scholar 

  64. Shan S, Su M, Li Y, Wang Z, Liu D, Zhou Y, et al. Mechanism of RhoA regulating benign prostatic hyperplasia: RhoA-ROCK-β-catenin signaling axis and static & dynamic dual roles. Mol Med. 2023;29(1):139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Shi J, Surma M, Yang Y, Wei L. Disruption of both ROCK1 and ROCK2 genes in cardiomyocytes promotes autophagy and reduces cardiac fibrosis during aging. Faseb J. 2019;33(6):7348–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Zhang G, Zhu F, Han G, Li Z, Yu Q, Li Z, et al. Silencing of URG11 expression inhibits the proliferation and epithelial-mesenchymal transition in benign prostatic hyperplasia cells via the RhoA/ROCK1 pathway. Mol Med Rep. 2018;18(1):391–8.

    CAS  PubMed  Google Scholar 

  67. Nimiritsky P, Novoseletskaya E, Eremichev R, Alexandrushkina N, Karagyaur M, Vetrovoy O. et al. Self-organization provides cell fate commitment in MSC sheet condensed areas via ROCK-dependent mechanism. Biomedicines. 2021;9(9):1192.

  68. Wróbel A, Doboszewska U, Rechberger E, Rojek K, Serefko A, Poleszak E, et al. Rho kinase inhibition ameliorates cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(6):613–9.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Wróbel A, Serefko A, Rechberger E, Banczerowska-Górska M, Poleszak E, Dudka J, et al. Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats. Eur J Pharmacol. 2018;837:127–36.

    Article  PubMed  Google Scholar 

  70. Pan T, Wang S, Feng H, Xu J, Zhang M, Yao Y, et al. Preclinical evaluation of the ROCK1 inhibitor, GSK269962A, in acute myeloid leukemia. Front Pharmacol. 2022;13:1064470.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007;320(1):89–98.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to extend our sincere appreciation to our colleagues for their invaluable efforts and insightful comments on this paper

Funding

Thanks for the financial support provided by the National Natural Science Foundation (No. 82370779), the Furong Scholars Program of Hunan Province and the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University (No.20210312) for this research.

Author information

Authors and Affiliations

  1. Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China

    Youyou Li, Jiaren Li, Liang Zhou & Long Wang

  2. Movement System Injury and Repair Research Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China

    Zhenxing Wang, Ling Jin, Jia Cao & Hui Xie

Authors
  1. Youyou Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiaren Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhenxing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ling Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jia Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hui Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Long Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Youyou Li conducted the experiments and data analysis, and drafted the original manuscript. Jiaren Li and Liang Zhou participated in the animal experiments for validation. Ling Jin, Zhenxing Wang and Jia Cao provided methodological guidance. Hui Xie and Long Wang reviewed and revised the manuscript. All authors read and approved the final paper.

Corresponding authors

Correspondence to Hui Xie or Long Wang.

Ethics declarations

Ethics approval and consent to participate

This experiment complies with the Declaration of Helsinki and was performed under the oversight and regulations of the ethics committee of the Third Xiangya Hospital (No. 22239). Animal experiments were performed in accordance with the Basel Declaration and under the approval and supervision of the Ethics Committee of Central South University (No. 2021sydw0039).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Li, J., Zhou, L. et al. Aberrant activation of TGF-β/ROCK1 enhances stemness during prostatic stromal hyperplasia. Cell Commun Signal 22, 257 (2024). https://0-doi-org.brum.beds.ac.uk/10.1186/s12964-024-01644-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12964-024-01644-4

Keywords

Cell Communication and Signaling

ISSN: 1478-811X